Fischesser Ryan 4
4 · Caribou Biosciences, Inc. · Filed May 6, 2022
Insider Transaction Report
Form 4
Fischesser Ryan
VP of Finance and Controller
Transactions
- Exercise/Conversion
Common Stock
2022-05-05$2.69/sh+1,136$3,056→ 114,380 total - Exercise/Conversion
Common Stock
2022-05-05$4.11/sh+1,138$4,677→ 115,518 total - Exercise/Conversion
Option to purchase Common Stock
2022-05-05−1,136→ 4,543 totalExercise: $2.69Exp: 2029-03-18→ Common Stock (1,136 underlying) - Exercise/Conversion
Option to purchase Common Stock
2022-05-05−1,138→ 18,176 totalExercise: $4.11Exp: 2031-03-29→ Common Stock (1,138 underlying)
Footnotes (3)
- [F1]Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021.
- [F2]1/4th of the shares subject to this option vested on January 1, 2020 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter so that the option is fully vested on January 1, 2023, subject to the reporting person's continues service to the Issuer through the applicable vesting dates.
- [F3]1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on January 1, 2025, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. The vesting schedule for this option was inadvertently described incorrectly in the reporting person's Form 3 filed on July 23, 2021.